Suchergebnisse - "Rossi, Francesca Maria"

PubPharm (81)

1

COVID-19 vaccination : Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients

enthalten in: Hematological oncology | 2023

von Del Poeta, G. | Laureana, R. | Bomben, R. | +16

CommentOn: Hematol Oncol. 2021 Dec;39(5):712-714. - PMID 34462939

2

The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

enthalten in: American journal of hematology | 2023

von Morabito, F. | Tripepi, G. | Mauro, F. | +28

3

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib : a campus CLL study

enthalten in: Leukemia | 2023

von Bomben, R. | Rossi, F. | Vit, F. | +26

4

Elastin MIcrofibriL INterfacer1 (EMILIN-1) is an alternative prosurvival VLA-4 ligand in chronic lymphocytic leukemia

enthalten in: Hematological oncology | 2022

von Tissino, E. | Pivetta, E. | Capuano, A. | +16

5

Elastin MIcrofibriL INterfacer1 (EMILIN‐1) is an alternative prosurvival VLA‐4 ligand in chronic lymphocytic leukemia

enthalten in: Hematological Oncology | 2022

von Tissino, E. | Pivetta, E. | Capuano, A. | +16

6

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

enthalten in: Haematologica | 2021

von Pozzo, F. | Bittolo, T. | Tissino, E. | +15

7

COVID-19 vaccination : Evaluation of risk for protection failure in chronic lymphocytic leukemia patients

enthalten in: Hematological oncology | 2021

von Del Poeta, G. | Bomben, R. | Polesel, J. | +14

CommentIn: Hematol Oncol. 2023 Aug;41(3):559-562. - PMID 36585917

8

TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Bomben, R. | Rossi, F. | Vit, F. | +34

9

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia

enthalten in: Haematologica | 2021

von Del Poeta, G. | Biagi, A. | Laurenti, L. | +13

10

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine : Results of study on 486 cases outside clinical trials

enthalten in: American journal of hematology | 2021

von Morabito, F. | Tripepi, G. | Del Poeta, G. | +46

1
2
3
4
5
6
7
8
9
Nächster »
[9]